SAFETY DATA FROM AN EXPANDED ACCESS PROGRAM (EAP) OF NIVOLUMAB (NIVO) IN COMBINATION WITH IPILIMUMAB (IPI) IN PATIENTS WITH ADVANCED MELANOMA (MEL)

被引：0
|
作者：
Chapman, Paul B. [1 ]
Sznol, Mario [2 ]
Lao, Christopher D. [3 ]
Gonzalez, Rene [4 ]
Daniels, Gregory A. [5 ]
Thompson, John A. [6 ]
Kudchadkar, Ragini R. [7 ]
Sharfman, William H. [8 ]
Atkins, Michael B. [9 ]
Pavlick, Anna C. [10 ]
Infante, Jeffrey R. [11 ]
Kim, Kevin B. [12 ]
Weber, Jeffrey S. [13 ]
Nair, Suresh [14 ]
Cowey, Lance [15 ]
Lipson, Evan J. [8 ]
Lee, Sue [16 ]
Avila, Alexandre [16 ]
Hodi, Stephen [17 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[4] Univ Colorado, Ctr Canc, Denver, CO 80262 USA
[5] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[6] Univ Washington, Seattle, WA 98195 USA
[7] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[8] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[9] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[10] NYU, New York, NY USA
[11] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[12] Calif Pacific Ctr Melanoma Res, San Francisco, CA USA
[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[14] Lehigh Valley Hosp, Allentown, PA USA
[15] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[16] Bristol Myers Squibb, Princeton, NJ USA
[17] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
219
引用
收藏
页码：119 / 119
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.
    Tawbi, Hussein Abdul-Hassan
    Forsyth, Peter A. J.
    Algazi, Alain Patrick
    Hamid, Omid
    Hodi, F. Stephen
    Moschos, Stergios J.
    Khushalani, Nikhil I.
    Gonzalez, Rene
    Lao, Christopher D.
    Postow, Michael Andrew
    Atkins, Michael B.
    Ernstoff, Marc S.
    Puzanov, Igor
    Kudchadkar, Ragini Reiney
    Thomas, Reena Parada
    Tarhini, Ahmad A.
    Jiang, Joel
    Avila, Alexandre
    Demelo, Sheena
    Margolin, Kim Allyson
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [42] Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean Jacques
    Cowey, C. Lance
    Lao, Christopher
    Schadendorf, Dirk
    Ferrucci, Pier Francesco
    Smylie, Michael
    Dummer, Reinhard
    Hill, Andrew
    Haanen, John B. A. G.
    Maio, Michele
    McArthur, Grant A.
    Walker, Dana
    Jiang, Joel
    Horak, Christine E.
    Larkin, James M. G.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Canadian cohort expanded-access program of nivolumab plus ipilimumab in advanced melanoma
    Hogg, D.
    Monzon, J. G.
    Ernst, S.
    Song, X.
    McWhirter, E.
    Savage, K. J.
    Skinn, B.
    Romeyer, F.
    Smylie, M.
    CURRENT ONCOLOGY, 2020, 27 (04) : 204 - 214
  • [44] Effect of nivolumab (NIVO) in combination with ipilimumab (IPI) versus IPI alone on quality of life (QoL) in patients (pts) with treatment-naive advanced melanoma (MEL): Results of a phase II study (CheckMate 069)
    Abernethy, Amy Pickar
    Postow, Michael Andrew
    Chesney, Jason Alan
    Grossmann, Kenneth F.
    Taylor, Fiona
    Coon, Cheryl
    Gilloteau, Isabelle
    Dastani, Homa
    Gagnier, Paul
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] CHECKMATE 067: A PHASE III RANDOMIZED DOUBLE-BLIND STUDY OF NIVOLUMAB (NIVO) MONOTHERAPY OR NIVO COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI MONOTHERAPY IN PREVIOUSLY UNTREATED PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL)
    Wolchok, J. D.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Rutkowski, P.
    Grob, J. J.
    Cowey, C. L.
    Lao, C. D.
    Schadendorf, D.
    Ferrucci, P. F.
    Smylie, M.
    Dummer, R.
    Hill, A.
    Haanen, J.
    Maio, M.
    McArthur, G.
    Yang, A.
    Rollin, L.
    Horak, C.
    Larkin, J.
    Hodi, F. S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 68 - 68
  • [46] CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy in previously untreated patients (pts) with advanced melanoma (MEL)
    Wolchok, J. D.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Rutkowski, P.
    Grob, J.
    Cowey, C. L.
    Lao, C. D.
    Schadendorf, D.
    Ferrucci, P. F.
    Smylie, M.
    Dummer, R.
    Hill, A.
    Haanen, J.
    Maio, M.
    McArthur, G.
    Yang, A.
    Rollin, L.
    Horak, C.
    Larkin, J.
    Hodi, F. S.
    ANNALS OF ONCOLOGY, 2015, 26 : 28 - 28
  • [47] Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis.
    Weber, Jeffrey S.
    Antonia, Scott Joseph
    Topalian, Suzanne Louise
    Schadendorf, Dirk
    Larkin, James M. G.
    Sznol, Mario
    Liu, Helen Y.
    Waxman, Ian
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.
    Hodi, F. Stephen
    Postow, Michael Andrew
    Chesney, Jason Alan
    Pavlick, Anna C.
    Robert, Caroline
    Grossmann, Kenneth F.
    McDermott, David F.
    Linette, Gerald P.
    Meyer, Nicolas
    Giguere, Jeffrey K.
    Agarwala, Sanjiv S.
    Shaheen, Montaser F.
    Ernstoff, Marc S.
    Minor, David R.
    Salama, April
    Taylor, Matthew Hiram
    Ott, Patrick Alexander
    Horak, Christine E.
    Gagnier, Paul
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Pembrolizumab Expanded Access Program (EAP) in Taiwan for patients with progressive advanced melanoma after prior ipilimumab treatment
    Yang, C-K.
    Liu, J-H.
    Lin, C-C.
    Liu, T-C.
    Cheng, P-T.
    Lin, C-Y.
    Hu, H-T.
    Cao, C-R.
    Huang, W-T.
    Chen, L-P.
    Chang, W-C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [50] Adjuvant nivolumab (NIVO) plus ipilimumab (IPI) for resected high-risk stages IIIC/IV melanoma (MEL).
    Khushalani, Nikhil I.
    Kim, Youngchul
    Gibney, Geoffrey Thomas
    Kudchadkar, Ragini Reiney
    Eroglu, Zeynep
    Markowitz, Joseph
    Czupryn, Maria P.
    Thebeau, Melissa S.
    McCormick, Lori
    Richards, Allison
    Weber, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345